BioIVT has bought Fidelis Research for an undisclosed price, marking the second acquisition for the biological specimens and services firm this month.
A little under two weeks ago, BioIVT snapped up Sekisui Chemical’s CRO division XenoTech. Financial terms for both transactions weren’t disclosed.
With the Fidelis acquisition, BioIVT takes ownership of an 85-site clinical biospecimen collection network across Southeastern Europe. Sofia, Bulgaria-headquartered Fidelis has cell isolation capabilities and provides custom contract research services for pharmaceutical companies and CROs, BioIVT said in a Sept. 26 release.
“This transaction further increases the scale and depth of BioIVT’s global operations by adding new clinical collection sites, which are predominantly hospital-based, focused on oncology, heme-oncology and autoimmune cases,” BioIVT CEO Richard Haigh said in the release. “We now have an exemplary global footprint for the collection and provision of high-quality, fully annotated, disease-state biospecimens in Europe, Asia and the U.S.”
BioIVT’s business model is centered on delivering highly characterized biospecimens that can accelerate medical breakthroughs by marrying samples with clinical, demographic, genetic and outcomes data. Over the last year it has focused its energy on creating the largest repository of biospecimens with mutation or genotype data.
The acquisition of Fidelis means the company can now expand its footprint into further therapeutic areas, including oncology.